Background. Subsequent to cyclophosphamide-based induction therapy of lupus nephritis, and despite maintenance chronic immunosuppressive treatment, many patients experience relapses. Methods. This prospective, observational study included 10 women with biopsy-proven relapse of proliferative lupus nephritis occurring during maintenance with mycophenolate mofetil (MMF) or azathioprine. The long-term outcome after a single course of the B-cell depleting anti-CD20 antibody rituximab (4 weekly infusions of 375 mg/m 2 ), combined with daily MMF (2 g) and prednisolone (0.5 mg/ kg/day for 4 weeks, tapered thereafter) is presented. Results. While renal function was not severely impaired at baseline, partial remission (>50% improvement in all abnormal renal parameters) was achieved in eight patients at a median of 3.5 months. In seven patients, with 24-h urinary protein of 2.5 ± 1.1 g (mean ± SD), complete remission, associated with increases in serum complement levels and decreases in anti-dsDNA titres, was subsequently established (normal serum creatinine/albumin levels, inactive urine sediment and 24-h urinary protein <0.5 g). Complete nephritis remission was sustained at the follow-up end (median of 38 months) in six patients. Combination treatment was well tolerated. Conclusions. The efficacy of this low-toxicity combination was particularly evident in patients with subnephrotic proteinuria due to proliferative lupus nephritis relapse. Controlled trials to define the role of rituximab/MMF in this condition are warranted.
Introduction
Systemic lupus erythematosus (SLE) is the archetypal systemic autoimmune disease in which various abnormalities in B-cell and T-cell tolerance are thought to underlie multiple organ damage [1] [2] [3] , including severe proliferative glomerulonephritis (class III or IV A or A/C of the 2003 ISN/RPS classification). This condition requires a powerful treatment aiming at induction of remission and prevention of relapses [4, 5] . However, chronic life-long maintenance therapy with steroids and cytotoxic agents is associated with the most damaging side effects and morbidity, and, despite such treatments, the cumulative relapse rate exceeds 40% at 5 years, frequently leading to renal disease progression [6] [7] [8] .
Cyclophosphamide-based regimens used to be the gold standard of therapeutic care for proliferative lupus nephritis [4, 9] . Mycophenolate mofetil (MMF), a more selective, and significantly less toxic than cyclophosphamide agent, is also efficacious in inducing and sustaining remission in many patients [9] [10] [11] [12] [13] [14] . On the other hand, growing evidence suggests that the anti-CD20 monoclonal antibody rituximab, an agent with an excellent safety profile, may prove a valuable alternative for lupus nephritis [1, [15] [16] [17] , including paediatric patients [18] .
We report here the first experience on the combination of a single course of rituximab and MMF as continuous induction/maintenance therapy in patients with relapsing proliferative lupus nephritis.
Patients and methods
Ten women, aged between 16 and 36 years, fulfilling the classification criteria of SLE [19] , with proliferative nephritis [5] experienced relapse between August 2004 and January 2006 (Table 1) . In those patients already on MMF, daily dose remained stable (2 g), or increased to 2 g. In addition to rituximab (four weekly infusions of 375 mg/m 2 ), prednisolone dose increased to 0.5 mg/kg/day orally for 4 weeks and tapered depending on patient's clinical status by 5 mg, either every 2 or 4 weeks, thereafter. Clinical and laboratory assessments, including flow cytometry studies for circulating B-cells (CD19+), were performed at baseline, at weeks 1, 2, 3 and 4, monthly for the first 12 months and bimonthly thereafter, as described [17] . The study was conducted according to the Declaration of Helsinki, had ethics board approval and informed consent was obtained.
Results
At the time of relapse diagnosis all patients presented with new active urine sediment and ( urinary protein excretion (mean ± SD from 0.5 ± 0.4 to 3.1 ± 1.3 g), whereas creatinine clearance was not severely impaired (from 87 ± 13 to 76 ± 14 ml/min). As shown in Table 2 , 8 of 10 patients achieved partial remission of nephritis, as defined in previous similar studies [17, 20] at a median of 3.5 months post baseline. Complete remission [17, 20] , defined as normal serum creatinine and albumin levels, inactive urine sediment and 24-h urinary protein <0.5 g, was subsequently established in seven patients.
Patients with subnephrotic proteinuria, albeit having the higher activity index in renal biopsy, seemed to be more susceptible in achieving remission, whereas those being in the nephrotic range responded to a lesser extent. As compared to full-responders, shorter B-cell depletion periods were noted in three patients with persisting active disease or partial remission. Complete remission of nephritis became evident either during the period of B-cell depletion or around the onset of B-cell regeneration in five of seven patients (Table 2) . Clinical remission was associated with profound increases in serum complement levels and/or decreases in anti-dsDNA titres ( Table 3) . Within the whole patient group an improvement in creatinine clearance was evident at the end of the follow-up (from 76 ± 14 at relapse to 94 ± 17 ml/min, P: 0.0002 by the paired t-test, Table 2 ). At a median of 38 months from baseline (June 2008) complete remission was sustained in six patients (Table 2) . Overall, the combination of a single course of rituximab and MMF was well tolerated. No serious or opportunistic infections were observed during the follow-up period.
Discussion
The rationale behind the use of a B-cell depleting agent in lupus nephritis lies on the central role of B-cells in SLE pathogenesis [2, 3, 15, 16, 21, 22] . Levels of anti-DNA antibodies, which may bind to the kidney basement membrane and instigate inflammation, were indeed decreased. Transient B-cell depletion could also attenuate the cytokine milieu and hence the function of other immune cells. Rituximab might also have acted through reductions of the cognate interactions between autoimmune T-helper cells and B-cells. Lymphocyte depletion studies in mice have shown that B-cells are important in the expression of lupus nephritis regardless of their ability to produce the antibody [2, 22] . Accordingly, rituximab administration in SLE decreased the activated phenotype of peripheral and tissue-resident autoimmune T-cells, probably by abolishing antigen presentation by B-cells (reviewed in 23). Enhancement of the numbers and function of regulatory T cells in rituximab-treated patients with SLE may also occur [24, 25] .
The relative contribution(s) of MMF and/or corticosteroids cannot be precisely determined. However, the following observations suggest a rituximab-specific beneficial effect: (a) at the time of relapse five of the eight responding patients had been already treated with MMF, (b) corticosteroid dose taken at the time of relapse remained stable in two patients who achieved complete remission; an additional responding patient had relapsed while being already on 20 mg of daily prednisolone. On the other hand, three responding patients had been treated with azathioprine before relapse and the good results could partly be attributed to MMF administration.
Considering the limitations of an observational study, and although the number of patients need to be increased, the data presented herein suggest that rituximab/MMF combination may be beneficial for patients with relapsing proliferative lupus nephritis, when promptly diagnosed and before severe renal damage occurs. Well-designed, properly powered trials should be conducted to precisely define the role of this low-toxicity treatment approach; such trials might document a superiority of rituximab/MMF to cyclophosphamide-based regimens for induction/ maintenance therapy of proliferative lupus nephritis. 19.4 ± 8.9 (P < 0.025) NA NA (P < 0.04) NA (P < 0.01)
